ALNYStockAlnylam Pharmaceuticals Inc
Verdicts genuinely change. Free email alert the moment ALNY's does — no target price to set, unlike a price alert.
Near limit Ratio screen, 4 of 7 decided standards passing. AAOIFI, Dow Jones Islamic, MSCI Islamic M-Series, S&P Shariah are within 3 points of their line. If they all crossed, the majority verdict would move from Compliant to Not compliant. What would change it
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Trade plan
Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
Alnylam Pharmaceuticals Inc (ALNY) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-06). See the full ratio breakdown and business-activity screen below for the reasoning.
This sits among 435 compliant Healthcare stocks we track. See compliant Healthcare stocks →
How the status reached this point
Compliant · status tracked since Nov 17, 2026
No change to ALNY’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.
Read once a day from the status this page publishes, last on Nov 21, 2026. The per-methodology record is under “What changed, and when” in the in-house research.
🕌 In-house Compliance Research
Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.
AAOIFI divides by the market cap: $22.1B as of 2026-11-16. At the 2026-11-20 close it is about $20.1B (the stored market cap moved by the share price since, not a new share count), and at that cap AAOIFI's interest-bearing debt ratio would read 1.2% (1.1% at the stored cap, against a 30% line) and interest-bearing investments ratio would read 17.8% (16.2% at the stored cap, against a 30% line). The published verdict changes only when the company is re-screened.
Business activity: cleared (no excluded categories detected)
AAOIFI Pass 3 of 3 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 1.13% | 30.00% | Pass(28.9pp buffer) |
| Interest-bearing investments | 16.23% | 30.00% | Pass(13.8pp buffer) |
| Non-permissible income | 3.00% | 5.00% | Pass(2.0pp buffer) |
Usmani Fail 4 of 5 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 3.12% | 33.00% | Pass(29.9pp buffer) |
| Interest-bearing investments | 44.89% | 33.00% | Fail(11.9pp over) |
| Non-liquid assets | 41.54% | at least 20.00% | Pass(21.5pp above the floor) |
| Non-permissible income | 3.00% | 5.00% | Pass(2.0pp buffer) |
| Net liquid assets per share | $2.6B | under mkt cap $22.1B | Pass |
MSCI Fail 2 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 3.12% | 33.33% | Pass(30.2pp buffer) |
| Cash + interest-bearing securities | 44.89% | 33.33% | Fail(11.6pp over) |
| Accounts receivable | 58.46% | 33.33% | Fail(25.1pp over) |
| Non-permissible income | 3.00% | 5.00% | Pass(2.0pp buffer) |
FTSE Fail 2 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 33.33% | Pass(33.3pp buffer) |
| Cash + interest-bearing securities | 44.89% | 33.33% | Fail(11.6pp over) |
| Accounts receivable | 58.46% | 50.00% | Fail(8.5pp over) |
| Non-permissible income | 3.00% | 5.00% | Pass(2.0pp buffer) |
Dow Jones Islamic Market Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.53% | 33.00% | Pass(32.5pp buffer) |
| Cash + interest-bearing securities | 7.60% | 33.00% | Pass(25.4pp buffer) |
| Accounts receivable | 2.30% | 33.00% | Pass(30.7pp buffer) |
| Non-permissible income | 3.00% | 5.00% | Pass(2.0pp buffer) |
S&P Shariah Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.60% | 33.00% | Pass(32.4pp buffer) |
| Cash + interest-bearing securities | 8.66% | 49.00% | Pass(40.3pp buffer) |
| Accounts receivable | 2.62% | 49.00% | Pass(46.4pp buffer) |
| Non-permissible income | 3.00% | 5.00% | Pass(2.0pp buffer) |
MSCI M-Series Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.60% | 33.33% | Pass(32.7pp buffer) |
| Cash + interest-bearing securities | 8.66% | 33.33% | Pass(24.7pp buffer) |
| Accounts receivable | 11.28% | 49.00% | Pass(37.7pp buffer) |
| Non-permissible income | 3.00% | 5.00% | Pass(2.0pp buffer) |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
How close is it to flipping?
Every current reading against its own line, closest first. A verdict is only as durable as that distance.
The numbers the ratios are built from
Read from ALNY's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.
| Line | Figure | As reported | Read from |
|---|---|---|---|
| RevenueTotal revenue for the period | $3.7B | 2025-12-31 | RevenueFromContractWithCustomerExcludingAssessedTax |
| Interest-bearing debtShort and long-term borrowings | $0 | 2026-09-30 | no debt tag reported in 3+ years (treated as $0) |
| Cash and interest-bearing securitiesCash, equivalents and marketable securities | $3.6B | 2026-09-30 | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents, AvailableForSaleSecuritiesDebtSecuritiesCurrent |
| Total assetsBalance sheet total | $8.0B | 2026-09-30 | Assets |
| Market capDenominator for AAOIFI | $22.1B | live quote | price x shares |
| 36-month average market capDenominator for S&P Shariah and MSCI M-Series | $36.0B | 756 trading days | closes x shares |
| 24-month average market capDenominator for Dow Jones Islamic Market | $41.2B | 504 trading days | closes x shares |
| Non-permissible revenueInterest and excluded income | $111.5M | 2025-12-31 | InvestmentIncomeInterest |
Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.
Sources
Filing information. Balance sheet as of 2026-09-30. Income statement as of 2025-12-31. Screened 2026-11-16.
Filing links appear after the next screen: this row was screened before filing citations were recorded.
-
Total assets$8.0B
Assets· balance sheet as of 2026-09-30 -
Interest-bearing debt$0
no debt tag reported in 3+ years (treated as $0)· balance sheet as of 2026-09-30 -
Cash and interest-bearing securities$3.6B
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents, AvailableForSaleSecuritiesDebtSecuritiesCurrent· balance sheet as of 2026-09-30 -
Receivables$1.1B
AccountsReceivableNetCurrent· balance sheet as of 2026-09-30 -
Revenue$3.7B
RevenueFromContractWithCustomerExcludingAssessedTax· income statement as of 2025-12-31 -
Interest income (non-permissible)$111.5M
InvestmentIncomeInterest· income statement as of 2025-12-31 -
Market cap$22.1BMarket-data quote at screen time, 2026-11-16 · not a filing figure, so no link
What changed, and when
Verdict history for ALNY. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
- 2026-11-16 Unverified → Fail filing re-screen
- 2026-11-16 Unverified → Pass filing re-screen
Tracked since 2026-09-07.
Revenue by business segment
How ALNY’s $3.7B of revenue for the fiscal year 2025-01-01 to 2025-12-31 splits across what it sells, as the company tags it in its own 10-K.
| Segment | Share | Revenue |
|---|---|---|
| AMVUTTRA | 62.3% | $2.3B |
| Net revenues from collaborations | 14.9% | $553.4M |
| GIVLAARI | 8.3% | $308.5M |
| OXLUMO | 5.1% | $191.4M |
| Royalty revenue | 4.7% | $174.0M |
| ONPATTRO | 4.7% | $172.8M |
These are the company’s own segment names and figures. They do not say whether a line of business is permissible; our business-activity screen does.
Source: 10-K filed 2026-02-12 (accession 0001628280-26-007497), read from its XBRL on SEC EDGAR. Shares are of total revenue; subtotals and overlapping cuts the filing also tags are left out, so the lines add up to the total.
What would change the status
The headline verdict is the majority of the decided ratio standards — 4 pass and 3 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-09-30; market cap as stored on 2026-11-16.
Within 3 points of the line
- AAOIFI non permissible income ratio: 2.0pp buffer
- Dow Jones Islamic non permissible income ratio: 2.0pp buffer
- S&P Shariah non permissible income ratio: 2.0pp buffer
- MSCI Islamic M-Series non permissible income ratio: 2.0pp buffer
AAOIFI, Dow Jones Islamic, MSCI Islamic M-Series, S&P Shariah are within 3 points of their line. If they all crossed, the majority verdict would move from Compliant to Not compliant.
The ratios that move with the share price
AAOIFI's debt ratio (1.1% against a 30% line) would only fail if the market cap fell by 96%, to $831.3M. At the 2026-11-20 close it would read 1.2%.
AAOIFI's investments ratio is $3.6B cash and interest-bearing investments over a market cap of $22.1B (as of 2026-11-16), 16.2% against a 30% line.
At the 2026-11-20 close the market cap is about $20.1B (the stored cap moved by the share price since), so this ratio would read 17.8%; the line is -41% from there. The published status changes only when the company is re-screened.
It would fail if the market cap fell to $12.0B (-46%), about $89.31 a share against $165.04 implied by the screen's own figures.
AAOIFI would then fail, and the majority verdict would move from Compliant to Not compliant (3 of 7 decided standards passing).
At the screen's market cap, cash and interest-bearing investments would have to rise by $3.0B to reach the line.
AAOIFI would then fail, and the majority verdict would move from Compliant to Not compliant (3 of 7 decided standards passing, counting every standard that divides the same figure).
Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.
Shariah-compliant alternatives
Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.
| Company | Market cap | Price, day |
|---|---|---|
| VRTXVertex Pharmaceuticals, Inc. | $121.1B | — |
| REGNRegeneron Pharmaceuticals, Inc. | $85.3B | — |
| ARGXArgen X SE - ADR | $64.3B | — |
| ONCBeOne Medicines Ltd. American Depositary Shares | $40.4B | — |
| INCYIncyte Corp. | $25.9B | — |
A dash means no fresh quote is cached for that symbol; this list does not fetch one.
Funds that hold ALNY
18 of the 252 funds whose filed holdings we currently hold own ALNY shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns ALNY.
Shariah funds| Fund | ALNY in fund | Fund compliant by weight |
|---|---|---|
| MNZL Manzil Russell Halal USA Broad Market ETF | 0.09% | 88% |
Widely held U.S. index funds. If you own one, you own ALNY through it. None of them is a Shariah fund; the last column is our look-through of each.
| Fund | ALNY in fund | Fund compliant by weight |
|---|---|---|
| QQQ Invesco QQQ Trust, Series 1 | 0.17% | 69% |
| VUG VANGUARD GROWTH INDEX FUND | 0.13% | 63% |
| IWF iShares Russell 1000 Growth ETF | 0.12% | 69% |
| VTI VANGUARD TOTAL STOCK MARKET INDEX FUND | 0.06% | 54% |
| ITOT iShares Core S&P Total U.S. Stock Market ETF | 0.06% | 54% |
| SCHB Schwab U.S. Broad Market ETF | 0.04% | 53% |
| Fund | ALNY in fund | Fund compliant by weight |
|---|---|---|
| ATHAX Heritage Fund Also ATHDX, ATHYX | 1.74% | 58% |
| TACMX AMCAP Fund | 1.15% | 56% |
| LMVRX ClearBridge Value Fund | 0.87% | 44% |
| TAGRX Fundamental Large Cap Core Fund | 0.87% | 39% |
| ANWFX New Perspective Fund | 0.18% | 57% |
| PPUPX LargeCap Growth Fund I | 0.18% | 64% |
| ADCYX Disciplined Growth Fund Also ADRRX | 0.13% | 71% |
| RFEBX American Funds Fundamental Investors | 0.10% | 51% |
| ACVAX Strategic Allocation: Aggressive Fund Also ASTAX | 0.10% | 39% |
| GCPYX Gateway Equity Call Premium Fund | 0.08% | 55% |
1 more fund
| Fund | ALNY in fund | Fund compliant by weight |
|---|---|---|
| CSXRX Calvert U.S. Large Cap Core Responsible Index Fund | 0.07% | 56% |
Sorted by ALNY’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names ALNY once, so a bond is not counted as the shares; 3 more funds name ALNY in a way we cannot separate from its bonds, and are not listed. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Baillie Gifford | Baillie Gifford & Co | $1,355M | 1.3% | 2026-09-30 |
| Dodge & Cox | Dodge & Cox | $495M | 0.3% | 2026-09-30 |
| David Shaw | D. E. Shaw & Co. | $373M | 0.2% | 2026-09-30 |
| Israel Englander | Millennium Management | $123M | 0.0% | 2026-09-30 |
| Ken Griffin | Citadel Advisors | $81M | 0.0% | 2026-09-30 |
| Joel Greenblatt | Gotham Asset Management | $37M | 0.1% | 2026-09-30 |
| Ray Dalio | Bridgewater Associates | $7M | 0.0% | 2026-09-30 |
| Jefferies | Jefferies Financial Group | $2M | 0.0% | 2026-09-30 |
| Azzad Asset Management | Azzad Asset Management | $1M | 0.1% | 2026-09-30 |
| Paul Tudor Jones | Tudor Investment Corp | $1M | 0.0% | 2026-09-30 |
| Sallie Krawcheck | Ellevest | $1M | 0.1% | 2026-09-30 |
| Caxton Associates | Caxton Associates LLP | $0M | 0.0% | 2026-09-30 |
| Lee Ainslie | Maverick Capital | $0M | 0.0% | 2026-09-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 26.50 | BUY |
| Stochastic %K (14) | 1.55 | BUY |
| CCI (20) | -82.81 | NEUTRAL |
| Williams %R (14) | -98.45 | BUY |
| MACD (12,26,9) | 0.32 | BUY |
| ROC (10) | -7.77 | SELL |
| Momentum (10) | -12.12 | SELL |
| EMA (10) | 155.57 | SELL |
| SMA (10) | 154.71 | SELL |
| EMA (20) | 168.95 | SELL |
| SMA (20) | 168.22 | SELL |
| EMA (30) | 180.80 | SELL |
| SMA (30) | 188.20 | SELL |
| EMA (50) | 198.14 | SELL |
| SMA (50) | 208.79 | SELL |
| EMA (100) | 227.11 | SELL |
| SMA (100) | 232.07 | SELL |
| EMA (200) | 272.73 | SELL |
| SMA (200) | 270.71 | SELL |
About Alnylam Pharmaceuticals Inc
Healthcare · Biotechnology
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Background via Yahoo Finance — informational, not part of the verdict.
Latest Signal — 2026-07-08
Stop 320.36 Now 143.82 Target 330.04
🟠 NOT YET
The main driver: lagging the market by 27.3%. More negatives than positives right now. The setup isn't ready — check back when the trend or RSI changes.
Scores: 1 bullish / 2 bearish
Weak — low conviction, small size or skip
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 64 |
| ⏰ 4H | BEARISH | 46 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is this a fatwa?
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Why can the standards disagree?
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
How often is this re-screened?
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
Do I need to purify dividends?
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-11-17 · Asset managers net 895049 (-19081)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.